FDA Panel Votes 17-6 Obesity Drugmakers Should Study Heart Risks; Watch Orexigen (OREX, VIVUS (VVUS), Arena (ARNA)
Tweet Send to a Friend
Get Alerts OREX Hot Sheet
Up)
Trade OREX Now!
An FDA panel has just voted 17-6 that obesity drugmakers should study heart risks.
Traders should watch Orexigen (Nasdaq: OREX), VIVUS (Nasdaq: VVUS) and Arena (Nasdaq: ARNA).
UPDATE: Orexigen shares closed down 1 percent, VIVUS shares closed up 4 percent, and Arena shares closed up 4 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Traders should watch Orexigen (Nasdaq: OREX), VIVUS (Nasdaq: VVUS) and Arena (Nasdaq: ARNA).
UPDATE: Orexigen shares closed down 1 percent, VIVUS shares closed up 4 percent, and Arena shares closed up 4 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- XenoPort (XNPT) Arbaclofen Placarbil Phase 3 Misses Endpoints
- Ligand Pharmaceuticals (LGND) Agreement with Merck KGaA Unit Terminated
- Santarus (SNTS) to Present Additional Data on UCERIS
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
